127 related articles for article (PubMed ID: 31005212)
21. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
[TBL] [Abstract][Full Text] [Related]
22. Glioblastoma survival is better analyzed on preradiotherapy MRI than on postoperative MRI residual volumes: A retrospective observational study.
De Barros A; Attal J; Roques M; Nicolau J; Sol JC; Charni S; Cohen-Jonathan-Moyal E; Roux FE
Clin Neurol Neurosurg; 2020 Sep; 196():105972. PubMed ID: 32512407
[TBL] [Abstract][Full Text] [Related]
23. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
[TBL] [Abstract][Full Text] [Related]
24. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
Khalifa J; Tensaouti F; Lotterie JA; Catalaa I; Chaltiel L; Benouaich-Amiel A; Gomez-Roca C; Noël G; Truc G; Péran P; Berry I; Sunyach MP; Charissoux M; Johnson C; Cohen-Jonathan Moyal E; Laprie A
J Neurooncol; 2016 Oct; 130(1):181-192. PubMed ID: 27502603
[TBL] [Abstract][Full Text] [Related]
25. Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.
Li C; Wang S; Serra A; Torheim T; Yan JL; Boonzaier NR; Huang Y; Matys T; McLean MA; Markowetz F; Price SJ
Eur Radiol; 2019 Sep; 29(9):4718-4729. PubMed ID: 30707277
[TBL] [Abstract][Full Text] [Related]
26. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
[TBL] [Abstract][Full Text] [Related]
27. Volumetric Analysis Using Low-Field Intraoperative Magnetic Resonance Imaging for 168 Newly Diagnosed Supratentorial Glioblastomas: Effects of Extent of Resection and Residual Tumor Volume on Survival and Recurrence.
Fukui A; Muragaki Y; Saito T; Maruyama T; Nitta M; Ikuta S; Kawamata T
World Neurosurg; 2017 Feb; 98():73-80. PubMed ID: 27989974
[TBL] [Abstract][Full Text] [Related]
28. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
29. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
[TBL] [Abstract][Full Text] [Related]
30. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Rulseh AM; Vymazal J
J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.
Elson A; Bovi J; Siker M; Schultz C; Paulson E
J Neurooncol; 2015 May; 122(3):549-58. PubMed ID: 25700835
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival.
Juan-Albarracín J; Fuster-Garcia E; Pérez-Girbés A; Aparici-Robles F; Alberich-Bayarri Á; Revert-Ventura A; Martí-Bonmatí L; García-Gómez JM
Radiology; 2018 Jun; 287(3):944-954. PubMed ID: 29357274
[TBL] [Abstract][Full Text] [Related]
33. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
34. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
35. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
36. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
Chaddad A; Sabri S; Niazi T; Abdulkarim B
Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
[TBL] [Abstract][Full Text] [Related]
37. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
[TBL] [Abstract][Full Text] [Related]
38. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.
Bennett IE; Field KM; Hovens CM; Moffat BA; Rosenthal MA; Drummond K; Kaye AH; Morokoff AP
J Neurooncol; 2017 Jan; 131(2):321-329. PubMed ID: 27896520
[TBL] [Abstract][Full Text] [Related]
39. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.
John F; Bosnyák E; Robinette NL; Amit-Yousif AJ; Barger GR; Shah KD; Michelhaugh SK; Klinger NV; Mittal S; Juhász C
Neuro Oncol; 2019 Feb; 21(2):264-273. PubMed ID: 30346623
[TBL] [Abstract][Full Text] [Related]
40. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.
Sun MZ; Oh T; Ivan ME; Clark AJ; Safaee M; Sayegh ET; Kaur G; Parsa AT; Bloch O
J Neurosurg; 2015 May; 122(5):1144-50. PubMed ID: 25768833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
